Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 92

Report ID: 1363

Chemotherapy-Induced Nausea and Vomiting (CINV) is one of the devastating side effects for patients undergoing cancer treatment. It is caused when various types of poisonous substances such as chemotherapeutic agents enter in the human body and alert the digestive system during chemotherapy. Besides chemotherapy, there are various types of factors that puts a patient high risk for CINV including female sex, history of alcohol use, CINV & motion sickness and anxiety or depression.
The global CINV & PONV market is expected to grow with increasing cancer incidence, growing female population, increasing pharmaceutical R&D spending, growing healthcare expenditure and accelerating economic growth. Key trends and developments of this market includes progressing drugs under pipeline, high demand for combination therapy and increasing preference for pressure point therapy. However, there are some factors which can hinder growth of the market including entry of generics, stringent regulations and treatment cost.
In 2018, the global Chemotherapy-Induced Nausea and Vomiting (CINV) market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Chemotherapy-Induced Nausea and Vomiting (CINV) status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Chemotherapy-Induced Nausea and Vomiting (CINV) development in United States, Europe and China.

The key players covered in this study
Merck
Eisai
ProStrakan
Helsinn Holding
Mundipharma
Qilu Pharma
Teva
Novartis
Heron Therapeutics
Roche
Mylan
Tesaro

Market segment by Type, the product can be split into
CINV
PONV

Market segment by Application, split into
Hospitals
Ambulatory Surgical Centers
Diagnostic Centers

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Chemotherapy-Induced Nausea and Vomiting (CINV) status, future forecast, growth opportunity, key market and key players.
To present the Chemotherapy-Induced Nausea and Vomiting (CINV) development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Chemotherapy-Induced Nausea and Vomiting (CINV) are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size Growth Rate by Type (2014-2025)
1.4.2 CINV
1.4.3 PONV
1.5 Market by Application
1.5.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Ambulatory Surgical Centers
1.5.4 Diagnostic Centers
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size
2.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Growth Trends by Regions
2.2.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Regions (2014-2025)
2.2.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Manufacturers
3.1.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue by Manufacturers (2014-2019)
3.1.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Concentration Ratio (CR5 and HHI)
3.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Key Players Head office and Area Served
3.3 Key Players Chemotherapy-Induced Nausea and Vomiting (CINV) Product/Solution/Service
3.4 Date of Enter into Chemotherapy-Induced Nausea and Vomiting (CINV) Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type (2014-2019)
4.2 Global Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application (2014-2019)

5 United States
5.1 United States Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2014-2019)
5.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Key Players in United States
5.3 United States Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type
5.4 United States Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application

6 Europe
6.1 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2014-2019)
6.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Key Players in Europe
6.3 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type
6.4 Europe Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application

7 China
7.1 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2014-2019)
7.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Key Players in China
7.3 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type
7.4 China Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application

8 Japan
8.1 Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2014-2019)
8.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Key Players in Japan
8.3 Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type
8.4 Japan Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2014-2019)
9.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Key Players in Southeast Asia
9.3 Southeast Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type
9.4 Southeast Asia Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application

10 India
10.1 India Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2014-2019)
10.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Key Players in India
10.3 India Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type
10.4 India Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application

11 Central & South America
11.1 Central & South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size (2014-2019)
11.2 Chemotherapy-Induced Nausea and Vomiting (CINV) Key Players in Central & South America
11.3 Central & South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Type
11.4 Central & South America Chemotherapy-Induced Nausea and Vomiting (CINV) Market Size by Application

12 International Players Profiles
12.1 Merck
12.1.1 Merck Company Details
12.1.2 Company Description and Business Overview
12.1.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
12.1.4 Merck Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2014-2019)
12.1.5 Merck Recent Development
12.2 Eisai
12.2.1 Eisai Company Details
12.2.2 Company Description and Business Overview
12.2.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
12.2.4 Eisai Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2014-2019)
12.2.5 Eisai Recent Development
12.3 ProStrakan
12.3.1 ProStrakan Company Details
12.3.2 Company Description and Business Overview
12.3.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
12.3.4 ProStrakan Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2014-2019)
12.3.5 ProStrakan Recent Development
12.4 Helsinn Holding
12.4.1 Helsinn Holding Company Details
12.4.2 Company Description and Business Overview
12.4.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
12.4.4 Helsinn Holding Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2014-2019)
12.4.5 Helsinn Holding Recent Development
12.5 Mundipharma
12.5.1 Mundipharma Company Details
12.5.2 Company Description and Business Overview
12.5.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
12.5.4 Mundipharma Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2014-2019)
12.5.5 Mundipharma Recent Development
12.6 Qilu Pharma
12.6.1 Qilu Pharma Company Details
12.6.2 Company Description and Business Overview
12.6.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
12.6.4 Qilu Pharma Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2014-2019)
12.6.5 Qilu Pharma Recent Development
12.7 Teva
12.7.1 Teva Company Details
12.7.2 Company Description and Business Overview
12.7.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
12.7.4 Teva Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2014-2019)
12.7.5 Teva Recent Development
12.8 Novartis
12.8.1 Novartis Company Details
12.8.2 Company Description and Business Overview
12.8.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
12.8.4 Novartis Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2014-2019)
12.8.5 Novartis Recent Development
12.9 Heron Therapeutics
12.9.1 Heron Therapeutics Company Details
12.9.2 Company Description and Business Overview
12.9.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
12.9.4 Heron Therapeutics Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2014-2019)
12.9.5 Heron Therapeutics Recent Development
12.10 Roche
12.10.1 Roche Company Details
12.10.2 Company Description and Business Overview
12.10.3 Chemotherapy-Induced Nausea and Vomiting (CINV) Introduction
12.10.4 Roche Revenue in Chemotherapy-Induced Nausea and Vomiting (CINV) Business (2014-2019)
12.10.5 Roche Recent Development
12.11 Mylan
12.12 Tesaro

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details